Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1893 in HFpEF (Phase II, China)
CTR20254429Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-1893 in heart failure with preserved ejection fraction (HFpEF), sponsored by Shandong Sende. Started Mar 2026; status: active.
02
Drugs
HRS-1893
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on CTR20254429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254429.